CRISPR治疗和ProBioGen注册合作和授权协议,以开发新的体内递送技术

ProBioGen logo2 CRISPR标志

马萨诸塞州的剑桥和波士顿。德国柏林,1月22,2019 / B金宝搏官网mg3C通讯社/ -CRISPR治疗这家生物制药公司专注于开发用于严重疾病的革命性基因药物ProBioGen德国首屈一指的服务和技术供应商,今天宣布了一项专注于创新发展的多年研究合作体内CRISPR/Cas9的交付方式充分利用了益生菌素现有的技术和专业知识。

“我们的CRISPR/Cas9平台对一系列毁灭性的、基因定义疾病具有变革潜力,”托尼说何,医学博士,执行副总裁,研究和开发CRISPR治疗。“为了确保我们实现这一潜力,我们继续寻求支持我们的计划开拓新的技术和能力。我们期待着与ProBioGen团队合作,并借助他们的专业知识,以增强在CRISPR / Cas9的体内输送我们的研究和开发工作。”

益生素的首席科学官Volker Sandig博士说:“我们很高兴与CRISPR对新技术的联合开发项目走上对于体内递送CRISPR / Cas9的。该协议结合的思想,知识和两家公司的经验,我们期待着通过此次合作加强CRIPSR Therapeutics公司的高度创新的方法。”

技术和合作的财务细节尚未披露。该合作包括的研究目标成功完成了CRISPR治疗的许可选项。


关于CRISPR治疗
CRISPR Therapeutics是一家领先的基因编辑公司,利用其自有的CRISPR/Cas9平台,专注于开发用于严重疾病的革命性基因药物。CRISPR/Cas9是一种革命性的基因编辑技术,可以对基因组DNA进行精确、直接的改变。CRISPR Therapeutics已经建立了一系列治疗方案,涵盖广泛的疾病领域,包括血红蛋白病、肿瘤学、再生医学和罕见病。为了加快和扩大其努力,CRISPR Therapeutics已经与拜耳公司(Bayer AG)、Vertex Pharmaceuticals和ViaCyte Inc等领先公司建立了战略合作关系。CRISPR Therapeutics AG公司总部设在瑞士楚格,在美国拥有全资子公司CRISPR Therapeutics,公司研发部门设在马萨诸塞州的剑桥,商业办公室设在英国伦敦。

关于ProBioGen
益生素是一个首屈一指的,柏林的专家,开发和制造复杂的治疗性糖蛋白。结合了两种最先进的开发平台,基于益生菌素的CHO。RiGHT®表达和制造平台,结合智能产品特异性技术,生产出性能优化的生物制剂。快速和完整的细胞系和工艺开发,全面的分析开发和遵循可靠的GMP生产由一个高技能和经验丰富的团队执行。所有的服务和技术都嵌入到一个全面质量管理体系中,以确保符合国际ISO和GMP标准(EMA/FDA)。益生素成立于1994年,是一家私营企业,位于德国柏林。

CRISPR前瞻性陈述
This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) clinical trials (including, without limitation, the timing of filing of clinical trial applications and INDs, any approvals thereof and the timing of commencement of clinical trials), development timelines and discussions with regulatory authorities related to product candidates under development by CRISPR Therapeutics and its collaborators; (ii) the number of patients that will be evaluated, the anticipated date by which enrollment will be completed and the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials; (iii) the scope and timing of ongoing and potential future clinical trials; (iv) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties; (v) the sufficiency of CRISPR Therapeutics’ cash resources; and (vi) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the outcomes for each CRISPR Therapeutics’ planned clinical trials and studies may not be favorable; that one or more of CRISPR Therapeutics’ internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics’ product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics’ product candidates; availability and timing of results from preclinical studies; whether results from a preclinical trial will be predictive of future results of the future trials; uncertainties about regulatory approvals to conduct trials or to market products; uncertainties regarding the intellectual property protection for CRISPR Therapeutics’ technology and intellectual property belonging to third parties; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K, and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website atwww.sec.gov。现有的和潜在的投资者被提醒不要过分依赖这些前瞻性的声明,因为这些声明只提到了他们做出的日期。CRISPR Therapeutics不承担任何义务或承诺更新或修改本新闻稿中包含的任何前瞻性声明,但法律要求的范围除外。



188bet体育滚球往来

CRISPR投资者联系:188bet体育滚球
苏珊金
这个电子邮件地址正在被保护,防止垃圾邮件。您需要启用JavaScript来查看它。

CRISPR媒体联系:188bet体育滚球
詹妮弗Paganelli
WCG代表CRISPR
+1 347 658 8290
这个电子邮件地址正在被保护,防止垃圾邮件。您需要启用JavaScript来查看它。

ProBioGen AG联188bet体育滚球系方式:
加布里埃莱施耐德博士
首席商务官
ProBioGen AG
Goethestr 54。
13086柏林,德国
49(0)30 924 006-0
这个电子邮件地址正在被保护,防止垃圾邮件。您需要启用JavaScript来查看它。

由B3C新闻专线出版,通过金宝搏官网mgNewronic®

饼干使我们更容易为您提供我们的服务。随着我们业务的使用您允许我们使用cookies。